KB-1213

MCLA129-METV1-hIgG1

Background

The MET gene product, a receptor tyrosine kinase, stands out as one of the most important oncogenes activated in cancer. Upon paracrine stimulation by its specific ligand-the Hepatocyte Growth Factor-MET controls a network of intracellular signals including pro-mitogenic, pro-invasive, and anti-apoptotic cues, essential during embryogenesis and tissue regeneration. The same signals, when aberrantly activated, are crucial during cell transformation. Dysregulation of MET activation results from receptor gene alterations (amplification, point mutations, or translocations) or transcriptional upregulation, involving either the receptor-sustaining MET overexpression-or the ligand that, in case of ectopic expression, triggers autocrine loops. In well-defined genetic conditions-namely MET gene amplification and/or exon 14 skipping-MET acts as a ‘driver’ to which tumor cells are ‘addicted’(i.e. MET is the oncogene that solely sustains transformation).

Specifications

Catalog Number:
KB-1213
Cell Line Name:
MCLA129-METV1-hIgG1
Price:
0
Host Cell Line:
EXPI-CHO
Target:
MET
Species Reactivity:
Human
Application:
ELISA
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA

References

1.Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol. 2010;11(12):834–848.  2.Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4(12):915–925.  3.Comoglio PM, Trusolino L, Boccaccio C. Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy. Nat Rev Cancer. 2018;18(6):341–358.  4.Duplaquet L, Kherrouche Z, Baldacci S, Jamme P, Cortot AB, Copin MC, et al. The multiple paths towards MET receptor addiction in cancer. Oncogene. 2018;37(24):3200–3215.  5. Orlando E, Aebersold DM, Medová M, Zimmer Y. Oncogene addiction as a foundation of targeted cancer therapy: the paradigm of the MET receptor tyrosine kinase. Cancer Lett. 2019;443:189–202.
Please enable JavaScript in your browser to complete this form.